Zhang Tao, Lu Beiyin, Yan Zhongheng, Huang Xiaojun, Lu Wei
Department of Health Policy and Management, Hangzhou Normal University, Hangzhou, People's Republic of China.
Office of the Vice President, Central Hospital of Hainan Province Western, Haikou, People's Republic of China.
Risk Manag Healthc Policy. 2022 Sep 5;15:1659-1669. doi: 10.2147/RMHP.S376516. eCollection 2022.
Based on the diagnosis-related groups payment, China developed an innovative episode-based payment scheme, called "payment method by disease types with point counting", to control health expenditures inflation. This study aimed to investigate the impacts of this new payment method on volume, expenditures, and efficiency in Chinese public hospitals.
The study sample consisted of 7 tertiary hospitals and 14 secondary hospitals in Jinhua (intervention group) and 4 tertiary hospitals and 14 secondary hospitals in Taizhou (control group). Monthly data points were collected for each sampled hospital from June 2016 to June 2019 using a self-administered questionnaire with impact evaluation indicators. Controlled interrupted time-series analysis was employed to estimate the effect of the new payment method.
The significant slowing trends in inpatient expenditures per visit (tertiary hospitals: β=-123.16, p=0.042; secondary hospitals: β=-89.24, p=0.021) and out-of-pocket payments (tertiary hospitals: β=-4.18, p=0.027; secondary hospitals: β=-4.87, p=0.019) were observed after policy intervention. However, outpatient expenditures per visit in tertiary (β=1.67, p=0.018) and secondary hospitals (β=1.24, p=0.003) rose faster with the new payment method. Additionally, payment reform also caused an increase in the number of inpatient visits (β=100.01, p=0.038) and reduced the length of stay (β=-0.10, p=0.036) in tertiary hospitals.
The introduction of payment method by disease types with point counting causes the cost containment for inpatient care, whereas the increase in outpatient expenditures. The findings suggest this new payment scheme has the potential for rollout in other areas, but the cost-shifting from the inpatient to outpatient setting should be prevented.
基于诊断相关分组支付,中国制定了一种创新的按病种点数付费支付方案,以控制医疗费用的上涨。本研究旨在调查这种新支付方式对中国公立医院的服务量、费用和效率的影响。
研究样本包括金华市的7家三级医院和14家二级医院(干预组)以及台州市的4家三级医院和14家二级医院(对照组)。使用包含影响评估指标的自填式问卷,收集了2016年6月至2019年6月期间每家抽样医院的月度数据点。采用对照中断时间序列分析来估计新支付方式的效果。
政策干预后,观察到每次住院费用(三级医院:β=-123.16,p=0.042;二级医院:β=-89.24,p=0.021)和自付费用(三级医院:β=-4.18,p=0.027;二级医院:β=-4.87,p=0.019)有显著的放缓趋势。然而,采用新支付方式后,三级医院(β=1.67,p=0.018)和二级医院(β=1.24,p=0.003)的每次门诊费用增长更快。此外,支付改革还导致三级医院住院人次增加(β=100.01,p=0.038),住院天数缩短(β=-0.10,p=0.036)。
按病种点数付费支付方式的引入导致住院费用得到控制,而门诊费用有所增加。研究结果表明,这种新的支付方案有在其他地区推广的潜力,但应防止费用从住院向门诊转移。